From original research invention to application technology improvement

we never stop pursuing innovation

R&D Approach

Iterative and Innovative Biologics Research and Development

The company has established an open biological drug R&D platform, adopted the IPD model to engage in R&D activities, and conducts R&D innovation through the “four-in-one” model. The company is equipped with research and development capabilities for biological drugs, covering the entire process from concept to finished product.

Under the IPD model, the company conducts product-orientated matrix project management. Through the implementation and promotion of the IPD management concept and system, product development transcends departmental boundaries, enabling personnel from various departments such as R&D, manufacturing, and sales & marketing to cooperate in various projects. This promotes R&D processes and technological innovation, thereby improving R&D efficiency and shortening product commercialization cycle. Furthermore, it can also improve R&D quality and the product success rate. The integrated team can drive product development, from the laboratory to commercialization.

Iterative and Innovative Biologics Research and Development

Perfusion culture technology platform for mammalian cells
The technology has been applied to large-scale commercial manufacturing of PUK. Compared with fed-batch culture technology, perfusion culture technology has lower requirements for bioreactor volume, higher degree of automation, and a more stable cell culture environment, which help reduce production costs, increase yield, improve production efficiency and stabilize quality. This technology can meet the cell culture requirements for protein drugs, monoclonal antibodies, bispecific antibodies, and other products from early development to commercialization.
Perfusion culture technology platform for mammalian cells
High-expressingcell line, high-efficiency screening
Compared with the traditional serum-attached culture production process that is still widely used domestically and abroad, the stable serum-free suspension culture technology of viral vectors can greatly reduce the production cost of viral vector drugs and improve the convenience and feasibility of process scale-up while reducing regulatory and quality risks related to serum.
High-expressingcell line, high-efficiency screening
Long-acting protein drug development technology
It can be used for the development of long-acting Fc fusion proteins and site-specific polyethylene glycolized recombinant protein drugs.
Long-acting protein drug development technology
Viral vector serum-free suspension culture technology
The stable serum-free suspension culture technology of viral vectors can greatly reduce the production cost of viral vector drugs and improve the convenience and feasibility of process scale-up while reducing regulatory and quality risks related to serum compared with the traditional serum-attached culture production process that is still widely used domestically and abroad.
Viral vector serum-free suspension culture technology